Review: taking Cellcept and Methylprednisolone together


Summary

Drug interactions are reported among people who take Cellcept and Methylprednisolone together. This review analyzes the effectiveness and drug interactions between Cellcept and Methylprednisolone. It is created by eHealthMe based on reports of 3,453 people who take the same drugs from FDA and social media, and is updated regularly.

You are not alone

Join a support group for people who take Cellcept and Methylprednisolone >>>

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA and social media since 1977. Our tools are free and anonymous. 86 million people have used us. 300+ peer-reviewed medical journals have referenced our original studies. Start now >>>


Cellcept

Cellcept has active ingredients of mycophenolate mofetil. It is often used in kidney transplant. (latest outcomes from Cellcept 16,598 users)

Methylprednisolone

Methylprednisolone has active ingredients of methylprednisolone. It is often used in rheumatoid arthritis. (latest outcomes from Methylprednisolone 22,611 users)

On Aug, 25, 2016

3,453 people who take Cellcept, Methylprednisolone are studied.


Number of reports submitted per year:

Cellcept and Methylprednisolone drug interactions.

Drug effectiveness over time:

Cellcept:
  • < 1 month: 0.0% - (0 of 0 people)
  • 1 - 6 months: 0.0% - (0 of 1 people)
  • 6 - 12 months: 0.0% - (0 of 0 people)
  • 1 - 2 years: 0.0% - (0 of 0 people)
  • 2 - 5 years: 50.0% - (1 of 2 people)
  • 5 - 10 years: 0.0% - (0 of 0 people)
  • 10+ years: 0.0% - (0 of 0 people)
  • not specified: 0.0% - (0 of 0 people)
Methylprednisolone:
  • < 1 month: 0.0% - (0 of 0 people)
  • 1 - 6 months: 0.0% - (0 of 1 people)
  • 6 - 12 months: 0.0% - (0 of 0 people)
  • 1 - 2 years: 0.0% - (0 of 0 people)
  • 2 - 5 years: 100.0% - (1 of 1 people)
  • 5 - 10 years: 100.0% - (1 of 1 people)
  • 10+ years: 0.0% - (0 of 0 people)
  • not specified: 0.0% - (0 of 0 people)

Drug effectiveness by gender:

Cellcept:
  • female: 33.0% - (1 of 3 people)
  • male: 0.0% - (0 of 0 people)
Methylprednisolone:
  • female: 66.0% - (2 of 3 people)
  • male: 0.0% - (0 of 0 people)

Drug effectiveness by age:

Cellcept:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 0.0% - (0 of 0 people)
  • 30-39: 0.0% - (0 of 0 people)
  • 40-49: 0.0% - (0 of 1 people)
  • 50-59: 0.0% - (0 of 0 people)
  • 60+: 50.0% - (1 of 2 people)
Methylprednisolone:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 0.0% - (0 of 0 people)
  • 30-39: 0.0% - (0 of 0 people)
  • 40-49: 0.0% - (0 of 1 people)
  • 50-59: 0.0% - (0 of 0 people)
  • 60+: 100.0% - (2 of 2 people)

Most common drug interactions over time *:

< 1 month:
  • cytomegalovirus infection
  • sepsis
  • pyrexia
  • blood creatinine increased
  • abdominal pain
  • diarrhoea
  • white blood cell count decreased
  • renal impairment
  • pancytopenia
  • respiratory failure
1 - 6 months:
  • cytomegalovirus infection
  • abdominal pain
  • nausea
  • diarrhoea
  • sepsis
  • blood creatinine increased
  • pyrexia
  • vomiting
  • kidney transplant rejection
  • multi-organ failure
6 - 12 months:
  • cytomegalovirus infection
  • white blood cell count decreased
  • hepatic function abnormal
  • abdominal pain
  • antinuclear antibody increased
  • epstein-barr virus associated lymphoproliferative disorder
  • sinusitis
  • varicella
  • pyrexia
  • blood creatinine increased
1 - 2 years:
  • diarrhoea
  • pyrexia
  • bile duct cancer
  • hepatic neoplasm malignant recurrent
  • pyelonephritis
  • squamous cell carcinoma
  • abdominal pain
  • anaemia
  • arthralgia
  • asthenia
2 - 5 years:
  • epstein-barr virus associated lymphoproliferative disorder
  • pyrexia
  • anaemia
  • hepatitis b
  • lymphoproliferative disorder
  • malabsorption
  • bronchopneumonia
  • cytomegalovirus viraemia
  • interstitial lung disease
  • osteonecrosis
5 - 10 years:
  • angiosarcoma
  • metastases to lung
  • pyrexia
  • proteinuria
  • asthenia
  • colon cancer
  • decreased appetite
  • dehydration
  • diarrhoea
  • disorientation
10+ years:
  • chronic obstructive pulmonary disease
  • concomitant disease progression
  • non-hodgkin's lymphoma
  • abdominal pain upper
  • blood creatinine increased
  • chronic allograft nephropathy
  • crepitations
  • diabetes mellitus
  • dyspnoea
  • hepatic steatosis
not specified:
  • cytomegalovirus infection
  • pyrexia
  • blood creatinine increased
  • transplant rejection
  • kidney transplant rejection
  • diarrhoea
  • sepsis
  • pneumonia
  • anaemia
  • renal impairment

Most common drug interactions by gender *:

female:
  • cytomegalovirus infection
  • pyrexia
  • sepsis
  • diarrhoea
  • blood creatinine increased
  • abdominal pain
  • nausea
  • anaemia
  • renal impairment
  • kidney transplant rejection
male:
  • cytomegalovirus infection
  • blood creatinine increased
  • pyrexia
  • kidney transplant rejection
  • diarrhoea
  • sepsis
  • transplant rejection
  • pneumonia
  • renal impairment
  • renal failure

Most common drug interactions by age *:

0-1:
  • pancytopenia
  • c-reactive protein increased
  • cytomegalovirus viraemia
  • pneumonia bacterial
  • disseminated intravascular coagulation
  • epstein-barr virus infection
  • infusion related reaction
  • infusion site erythema
  • pyrexia
  • serum sickness
2-9:
  • abdominal pain
  • hepatic function abnormal
  • white blood cell count decreased
  • antinuclear antibody increased
  • sinusitis
  • varicella
  • multi-organ failure
  • sepsis
  • hypertension
  • drug ineffective
10-19:
  • pyrexia
  • nephropathy toxic
  • transplant rejection
  • diarrhoea
  • drug ineffective
  • cytomegalovirus infection
  • hypertension
  • convulsion
  • proteinuria
  • bone marrow failure
20-29:
  • cytomegalovirus infection
  • diarrhoea
  • blood creatinine increased
  • ureteric anastomosis complication
  • nausea
  • kidney transplant rejection
  • vomiting
  • renal tubular disorder
  • decreased appetite
  • blood sodium decreased
30-39:
  • cytomegalovirus infection
  • pyrexia
  • blood creatinine increased
  • diarrhoea
  • kidney transplant rejection
  • sepsis
  • transplant rejection
  • nausea
  • peritonitis
  • pneumonia
40-49:
  • cytomegalovirus infection
  • pyrexia
  • kidney transplant rejection
  • blood creatinine increased
  • transplant rejection
  • renal impairment
  • sepsis
  • anaemia
  • pneumonia
  • urinary tract infection
50-59:
  • cytomegalovirus infection
  • kidney transplant rejection
  • pyrexia
  • sepsis
  • blood creatinine increased
  • pneumonia
  • renal impairment
  • multi-organ failure
  • transplant rejection
  • anaemia
60+:
  • cytomegalovirus infection
  • blood creatinine increased
  • septic shock
  • sepsis
  • pyrexia
  • abdominal pain
  • leukopenia
  • renal impairment
  • respiratory failure
  • pneumonia

* Approximation only. Some reports may have incomplete information.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Do you take Cellcept and Methylprednisolone?

Can you answer these questions?

More questions for: Cellcept, Methylprednisolone

You may be interested in these reviews

More reviews for: Cellcept, Methylprednisolone

On eHealthMe, Cellcept (mycophenolate mofetil) is often used to treat kidney transplant. Methylprednisolone (methylprednisolone) is often used to treat rheumatoid arthritis. Find out below the conditions the drugs are used for and how effective they are.

What is the drug used for and how effecitve is it:


NOTE: The study is based on active ingredients and brand name. Other drugs that have the same active ingredients (e.g. generic drugs) are NOT considered.

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.